In another study [59], PDAC patients with high serum levels of IL-6 and IL-1β demonstrated inferior median overall survival (79 vs. 306 days, p < 0.001), progression-free survival (46 vs.158 days, p < 0.001), and tumor control rate following gemcitabine (20% vs. 76%, p < 0.001) than those with low levels of both cytokines. Here, IL6 is linked to neoplasm.